New obesity drug SRSD384 enters human testing
NCT ID NCT07557355
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new injectable drug called SRSD384 in 78 overweight or obese adults. In the first part, participants receive a single dose of SRSD384 alone. In the second part, they receive SRSD384 combined with another weight-loss drug, tirzepatide. The main goal is to check safety and how the drug moves through the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SRSD384 injection
What this could lead to
If successful, this could point toward a new weight-loss treatment option for people with obesity, possibly combined with existing drugs like tirzepatide.
What could go wrong
This is an early-phase trial with only 78 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to show meaningful weight loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES MELLITUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
NovaTrials
Charlestown, New South Wales, 2290, Australia
Contact